Diabetic Macular Edema
📧 Sign up to get email alerts when something new happens for Diabetic Macular Edema.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: Pilot and Phase 2 Study of the Efficacy of a Treatment Protocol With Dexamethasone Implant Loading Dose in Patients With Diabetic Macular Edema (LOADEX) [Phase 2]
This entry notes a pilot and Phase 2 study evaluating a loading-dose dexamethasone intravitreal implant protocol for diabetic macular edema,…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema [Phase 2]
Phase 2 clinical trial evaluating the effect of levosulpiride on retinal alterations in patients with diabetic retinopathy and diabetic macu…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: OCT-Based Screening for Early Retinal Changes in Asymptomatic Diabetic Patients
A clinical trial entry describes OCT-based screening to detect early retinal changes in asymptomatic diabetic patients, focusing on diabetic…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy [NA]
Clinical trial evaluating single-session versus multiple-session panretinal photocoagulation for proliferative diabetic retinopathy, with re…
-
EMA approval · 2025-11-14EMA Authorised: Epruvy (previously Ranibizumab Midas) (ranibizumab) — Midas Pharma GmbH
Epruvy, a new marketed form of ranibizumab by Midas Pharma, has been authorised for treating wet age-related macular degeneration, macular e…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-11-14EMA Authorised: Ranivisio (ranibizumab) — Midas Pharma GmbH
The EMA authorised Ranivisio (ranibizumab) for ocular indications including wet age-related macular degeneration, macular edema, and diabeti…
-
EMA approval · 2025-11-13EMA Authorised: Afiveg (aflibercept) — STADA Arzneimittel AG
The EMA has authorised Afiveg, an aflibercept product by STADA, for multiple retinal conditions including wet age-related macular degenerati…
-
FDA approval · 2025-11-12FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
The FDA approved a supplemental Biologics License Application for BYOOVIZ (ranibizumab-nuna) from Biogen, expanding regulatory clearance for…
-
EMA approval · 2025-11-12EMA Authorised: Eyluxvi (aflibercept) — Biolitec pharma Limited Zweigniederlassung Jena
EMA authorised Eyluxvi (aflibercept) from Biolitec pharma Limited Zweigniederlassung Jena for treatment of wet age-related macular degenerat…
-
EMA approval · 2025-11-07EMA Authorised: Baiama (aflibercept) — Formycon AG
EMA authorised Baiama, a biosimilar aflibercept from Formycon AG, for multiple retinal diseases including wet age-related macular degenerati…
-
EMA approval · 2025-11-07EMA Authorised: Ahzantive (aflibercept) — Formycon AG
EMA authorised Ahzantive (aflibercept) from Formycon AG for several retinal diseases including wet age-related macular degeneration and diab…
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: Imaging Parameters and DME Treatment Response
A completed clinical trial update examining imaging parameters and treatment response in diabetic macular edema and diabetic retinopathy.
-
EMA approval · 2025-11-04EMA Authorised: Vgenfli (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
The EMA authorized Vgenfli (aflibercept) from Polpharma for multiple retinal diseases, including wet age-related macular degeneration, macul…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration [Phase 4]
This Phase 4 trial studied blood levels of aflibercept after high-dose injections in both eyes for diabetic macular edema or neovascular age…
-
CLINICAL_TRIALS research · 2025-10-30Clinical Trial Update: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of KHK4951 in diabetic macular edema is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-10-22Clinical Trial Update: A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema [Phase 2]
A Phase 2 trial of the investigational drug Vamikibart (RO7200220) for diabetic macular edema has completed.
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema [Phase 2]
Phase 2 study evaluating Vamikibart in combination with Ranibizumab for diabetic macular edema has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: A Single Ascending Dose Cohort Study of AG-73305 in DME Patients [Phase 2]
A Phase 2 single ascending dose cohort study of AG-73305 in diabetic macular edema has completed, and results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) [Phase 3]
A phase 3b, single-arm study evaluating aflibercept 8 mg every 4 weeks in adults with neovascular age-related macular degeneration or diabet…
-
CLINICAL_TRIALS trial_result · 2025-10-03Clinical Trial Update: Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME) [Phase 2]
This update covers a Phase 2 trial evaluating RZ402 for diabetic macular edema. The study status is shown as COMPLETED.
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema [Phase 1]
A Phase 1 clinical trial evaluating intranasal octreotide for the treatment of diabetic macular edema. The study is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients [Phase 2]
A Phase 2a clinical trial is evaluating the safety, tolerability, and efficacy of SNP318 in diabetic macular edema (DME); the study is curre…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema [Phase 1]
This clinical trial update indicates that the investigational drug MS-553 is in Phase 1 testing for diabetic retinopathy with central-involv…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: 4D-150 in Patients With Diabetic Macular Edema [Phase 2]
Phase 2 trial update for 4D-150 in diabetic macular edema; the study is active but not recruiting.
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China
A real-world safety study evaluating OZURDEX in adults with diabetic macular edema in China; the trial is currently active but not recruitin…